BRAINSTORM CELL THERAPEUTICS

Company snapshot

BrainStorm Cell Therapeutics Inc. (NASDAQ) develops autologous stem cell therapies for neurodegenerative disorders such as ALS, MS, and Parkinson’s disease. These diseases have limited treatment options and represent unmet medical needs. NurOwn® is BrainStorm’s proprietary process for differentiating autologous mesenchymal stem cells (MSC) into neurotrophic factor (NTF)-secreting cells, transplant

• 5 active pipeline program(s) linked via ClinicalTrials.gov.
• 8 US patent(s) indexed to this assignee profile.
• 5 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for BRAINSTORM CELL THERAPEUTICS. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for BRAINSTORM CELL THERAPEUTICS.

1. Jun 8, 2026 Clinical update

   MSC-NTF-002-HMO-CTIL — Phase 2

2. Jun 8, 2026 Clinical update

   MSC-NTF cells transplantation (IM) — Phase 2

3. Jun 5, 2026 Clinical update

   NurOwn (MSC-NTF cells) — Phase 2

4. Jun 5, 2026 Clinical update

   NurOwn® (MSC-NTF cells) — Phase 3

5. Jun 5, 2026 Clinical update

   Debamestrocel - MSC-NTF (NurOwn) — Phase 3

View all clinical trial activity →

• What is BRAINSTORM CELL THERAPEUTICS?

  Brainstorm Cell Therapeutics is a biotech organization headquartered in NEW YORK, NY, USA. It trades on NYSE under ticker BCLI. Primary therapeutic focus areas include Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis, Multiple Sclerosis, Chronic Progressive. Nov

• Is BRAINSTORM CELL THERAPEUTICS publicly traded?

  Yes. BRAINSTORM CELL THERAPEUTICS is listed with ticker BCLI on NYSE per SEC EDGAR records linked on this profile.

• What drugs does BRAINSTORM CELL THERAPEUTICS develop or market?

  We link 5 drug profile(s) where BRAINSTORM CELL THERAPEUTICS is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/brainstorm-cell-therapeutics-inc#company-drugs.

• What are the latest developments for BRAINSTORM CELL THERAPEUTICS?

  In the last 12 months our linked public records show 5 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does BRAINSTORM CELL THERAPEUTICS focus on?

  BRAINSTORM CELL THERAPEUTICS focuses on Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis, Multiple Sclerosis, Chronic Progressive based on our analysis of their pipeline programs and drug development activities.